Osteoporosis International · Nov 17, 2026

Vitamin D replacement in adults and elderly in the Middle East and North Africa region: an updated systematic review and meta-analysis of randomized controlled trials

By Assaad M, Slim A, Sleem B et al.

Vitamin D deficiency remains highly prevalent in the Middle East and North Africa. This updated review of regional trials shows that moderate daily supplementation effectively raises vitamin D levels in most adults, while higher doses provide little extra benefit. These findings inform practical, evidence-based dosing recommendations for the region. Objective To update the evidence on the effects of vitamin D supplementation on serum 25-hydroxyvitamin 25(OH)D levels in healthy adults and elderly populations in the MENA region, and to assess the dose-response relationship. Methods We updated a prior systematic review and meta-analysis following the PRISMA 2020 guidelines. We identified randomized controlled trials from MENA countries evaluating oral vitamin D supplementation for ≥3 months in adults or older adults, through PubMed, Embase, and Cochrane Library searches (until December 2024). Trials compared different dosing regimens or placebo. We extracted data on baseline and achieved 25(OH)D, dose, duration, and adverse events. We assessed the risk of bias (ROB) using the Cochrane tool (2019). We calculated weighted mean differences (WMD) in the achieved 25(OH)D and the proportion of individuals achieving ≥20 ng/mL by dose category. We conducted a meta-regression to identify the predictors of response. Results Sixty-four trials were included (61 adult trials, 3 elderly trials). The weighted mean baseline 25(OH)D levels were 19.5 ng/ml in adults and 14.5 ng/ml in the elderly. In adults, high dose vitamin D supplementation (>2000 IU/d) may result in a large increase in 25(OH)D levels compared to placebo (42 trials, WMD 19.4 ng/ml; 95% CI: 16.5–22.3) (based on a low level of evidence), with 92% and 47.3% achieving ≥20 ng/mL in the high dose and the placebo arms, respectively (the placebo proportion was pooled across control groups of all included trials). Intermediate doses (800–2000 IU/day) may increase 25(OH)D compared to placebo (WMD 9.5 ng/mL; 95% CI: 6.5–12.5) (based on a low level of evidence), with 82.5% and 47.3% reaching ≥20 ng/mL, in the intermediate dose and placebo arms, respectively. The meta-regression showed that baseline 25(OH)D, BMI and supplementation dose were significant predictors, with each additional 100 IU/day increasing serum 25(OH)D by 0.4 ng/mL. Adverse events reporting was limited. Conclusions In adults and older adults from the MENA, intermediate vitamin D doses (1000–2000 IU/day) are sufficient for most individuals to achieve adequate 25(OH)D levels defined as ≥20 ng/mL, consistent with the Institute of Medicine/National Academy of Medicine recommendations; while higher doses provide limited additional benefit. These findings support region-specific supplementation strategies to guide clinical and public health practice.

doi.org/10.1007/s00198-026-08257-2PubMed 43043418Interventions

AgingResearch.News